Blog Labcorp Launches Test For Alzheimer’s Diagnosis Targeting  Biomarkers.

Labcorp Launches Test For Alzheimer’s Diagnosis Targeting  Biomarkers.

Labcorp, a leading diagnostics company, has introduced the Amyloid-Tau-Neurodegeneration (ATN) Profile test to U.S. physicians, aiming to expedite the diagnosis of Alzheimer’s disease. This innovative blood test detects biomarkers associated with the hallmarks of Alzheimer’s, potentially facilitating early diagnosis and treatment (Source: Economic Times).

While the ATN Profile test does not provide a definitive Alzheimer’s diagnosis, it serves as a convenient tool for physicians to identify patients who require further comprehensive testing. The test focuses on detecting amyloid plaques and tau tangles, the hallmark proteins found in Alzheimer’s patients, which gradually lead to the deterioration of brain cells, memory loss, and cognitive decline.

The traditional methods for detecting these changes involve invasive procedures like cerebrospinal fluid (CSF) tests, requiring lumbar punctures, or costly PET brain scans, often without insurance coverage. The ATN test offers a less invasive and more accessible approach to identifying potential Alzheimer’s cases.

Patients who receive a positive ATN test result would still need to undergo a CSF test or PET scan to confirm an Alzheimer’s diagnosis. However, those with a negative result can avoid the need for further advanced tests and instead explore assessments for other neurodegenerative conditions.

Alzheimer’s disease is responsible for a significant portion of dementia cases, estimated at around 60%. With the Labcorp ATN Profile, patients, along with their healthcare providers, can have a valuable tool to initiate the diagnostic process more efficiently.

The ATN Profile is currently priced at $626 and falls under the category of lab-developed tests, which do not require FDA approval. However, the FDA recently proposed new regulations for diagnostic tests to ensure safety and effectiveness, potentially impacting tests like the ATN Profile in the future.

Labcorp has also begun discussions with various health insurance providers, including the U.S. government’s Medicare program for those aged 65 and older, to explore reimbursement terms for the test.

Labcorp’s Chief Medical and Scientific Officer, Brian Caveney, emphasized that the company is collaborating with academic researchers to assess the ATN Profile’s effectiveness in identifying potential Alzheimer’s cases. In case regulatory changes occur, Labcorp is committed to adapting to the new rules while continuing to provide valuable diagnostic solutions in the field of neurodegenerative diseases.

The ATN Profile marks a significant step toward more accessible and early Alzheimer’s detection, offering hope for improved patient outcomes and more effective treatments in the future.

Also Read

0 0 votes
Article Rating